MOPEAD

Models of patient engagement for Alzheimer’s disease
MOPEAD logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115985

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
2 043 000
EFPIA in kind
1 967 251
Other
571 717
Total Cost
4 581 968

Summary

Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and determine which models work best in different situations. As well as adding to our understanding of the earliest stages of dementia, the project will facilitate recruitment for clinical trials and, most importantly, ensure that patients are able to access support from early on in their disease.

Achievements & News

MOPEAD project begins patient recruitment
May 2018

IMI’s MOPEAD project has recruited its first patients in studies designed to identify people who may have early stage Alzheimer’s disease. Currently, many people with Alzheimer’s disease only receive a diagnosis when their disease is relatively advanced. The MOPEAD project is trialling different approaches, tools and mechanisms to engage communities ###and ensure people with Alzheimer’s disease receive the support they need as early as possible. The project is testing four broad strategies in Spain (where the first patients were recruited) as well as Germany, the Netherlands, Slovenia, and Sweden. People who take part in the study will undergo screening for mild cognitive impairment and, if needed, more extensive tests. If the tests show the person may have early stage Alzheimer’s disease, they will be offered support and resources including access to clinical trials as well as recommendations to improve their quality of life.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Fundacio Ace, Barcelona , Spain
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Karolinska Institutet, Stockholm, Sweden
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Stichting Vumc, Amsterdam, Netherlands
  • Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Alzheimer Europe, Luxembourg, Luxembourg
  • Asdm Consulting, Bruxelles, Belgium
  • European Institute Of Women'S Health Limited, Dublin, Ireland
  • Modus Research And Innovation Limited, Dundee, United Kingdom
Patient organisations
  • Slovensko Zdruzenje Za Pomoc Pri Demenci - Spomincica Alzheimer Slovenija, Ljubljana, Slovenia
Third parties
  • Stockholms Lans Landsting, Stockholm, Sweden
Non EFPIA companies
  • Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain

CONTACT

Project coordinator
Miren GURRUTXAGA
FUNDACIO ACE
miren[at]fundacioace.com
Project leader
Laura Campo
Eli & Lilly
campo_laura[at]lilly.com